Device Trial Radar · NCT07339384
Signatera Assessment in Early-Stage Endometrial Cancer
Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,010
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Oct 2034
Study completion Oct 2034
Sponsor
- Lead sponsor
- Natera, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer. The main question it aims to answer is: • To evaluate if 3-year recurrence-free survival among women with Stage I, high-intermediate risk endometrial cancer who are ctDNA negative after receiving ctDNA-guided observation is non-inferior to adjuvant vaginal brachytherapy (an internal radiation therapy) Researchers will compare high-risk intermediate ctDNA negative participants who are observed to those who receive vaginal brachytherapy to see if they have similar outcomes. Participants will be asked to: * Receive serial ctDNA testing * Visit their study doctor per their standard of care visits about every 3 months for 2 years * Answer a questionnaire about their well-being
Conditions
- Endometrial Cancer
Interventions
Signatera Genome ultra-sensitive ctDNA blood testDevice
Signatera Genome is intended for use as a post-surgical risk stratification tool for patients with early-stage HIR endometrial cancer. The test is used to identify patients with no evidence of MRD following definitive surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence Free Survival (RFS)Time frame: 3 years from randomization to the first occurrence of disease recurrence or death from any cause, whichever occurs first
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Hospital
Birmingham, Alabama
University of California, San Diego
La Jolla, California
University of California, Los Angeles
Los Angeles, California
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.